SMNR (Semnur Pharmaceuticals) ROCE %: 0.00% (As of Mar. 2026)


SMNR Semnur Pharmaceuticals Inc SMNR
8 GF Score
Price $0.85
View Full Analysis

What is Semnur Pharmaceuticals ROCE %?

Semnur Pharmaceuticals SMNR +30.77% 8 ROCE % is 0.00% as of Mar. 2026. GuruFocus rates SMNR with a GF Score™ of 8/100.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Semnur Pharmaceuticals's annualized ROCE % for the quarter that ended in Mar. 2026 was 0.00%.

Semnur Pharmaceuticals  (OTCPK:SMNR) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Semnur Pharmaceuticals ROCE % Related Terms

Semnur Pharmaceuticals ROCE % Historical Data

* Premium members only.

The historical data trend for Semnur Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Semnur Pharmaceuticals ROCE % Chart

Semnur Pharmaceuticals Annual Data
Trend Dec22 Dec23 Dec24 Dec25
ROCE %
-664.02 -1,743.85 -145.29 0.00

Semnur Pharmaceuticals Quarterly Data
Dec22 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -38.12 -53.17 0.00 0.00 0.00
SMNR
8GF Score
Semnur Pharmaceuticals Inc SMNR
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Semnur Pharmaceuticals ROCE % Calculation

Semnur Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-160.416/( ( (6.684 - 0.035) + (1.346 - 10.168) )/ 2 )
=-160.416/( (6.649+-8.822)/ 2 )
=-160.416/-1.0865
=14,764.47 %

Semnur Pharmaceuticals's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-18.304/( ( (1.346 - 10.168) + (1.969 - 10.38) )/ 2 )
=-18.304/( ( -8.822 + -8.411 )/ 2 )
=-18.304/-8.6165
=0 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 0.00% mean?
Semnur Pharmaceuticals (SMNR) has a ROCE % of 0.00% as of Mar. 2026.
Is Semnur Pharmaceuticals' ROCE % too high?
Semnur Pharmaceuticals' current ROCE % is 0.00%. Overall, Semnur Pharmaceuticals has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Semnur Pharmaceuticals' ROCE % compare to CNTB and ENLV?
Semnur Pharmaceuticals' ROCE % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Semnur Pharmaceuticals's current ROCE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Semnur Pharmaceuticals stock overvalued right now?
Semnur Pharmaceuticals (SMNR) has a current ROCE % of 0.00%. The current ROCE % is 0.00%. Semnur Pharmaceuticals' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Semnur Pharmaceuticals (SMNR), the current ROCE % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Semnur Pharmaceuticals Business Description

Address 960 San Antonio Road, Palo Alto, CA, USA, 94303
Semnur Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its main product candidate, SP-102 (10 mg, dexamethasone sodium phosphate viscous gel), is being developed as a non-opioid novel injectable corticosteroid gel formulation for patients with moderate to severe LRP (also known as sciatica), containing no preservatives, surfactants, solvents, or particulates.
8GF Score

Get the complete analysis for SMNR

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.85
Price